lifestyle.pluralist.com

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Written by

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate – NEWSnet – News… as it used to be

More Press Releases

April 14, 2026

Harley-Davidson, Inc. to Host Audio Webcast to Provide an Investor Discussion of Harley-Davidson Financial Services (HDFS) on Thursday, April 16, 2026

April 14, 2026

U.S. DISTRICT COURT FINDS BUSINESSMAN ALEX ROVIROSA INNOCENT IN HISTORIC REBUKE OF DOJ’S BASELESS PROSECUTION

April 14, 2026

Are OMEX, CRBG, AFBI Obtaining Fair Deals for their Shareholders?

April 14, 2026

Rosen Law Firm Encourages Barclays PLC Investors to Inquire About Securities Class Action Investigation – BCS